Rituximab in lymphocyte predominance Hodgkin's disease: a case series.
Publication/Presentation Date
9-1-2003
Abstract
Rituximab in combination with chlorambucil or radiation therapy may be an effective and less-toxic therapeutic alternative for patients with lymphocyte predominance Hodgkin's disease (LPHD). We treated 6 patients with LPHD with weekly rituximab at 375 mg/m2 for 4 weeks, followed by either radiation therapy or chlorambucil. Four patients had previously untreated disease and 2 had relapsed LPHD. All patients had no evidence of disease progression at a median follow-up time of 12.5 months after receiving rituximab therapy (range, 6-39 months) and a median follow-up time of 6.5 months after completion of chlorambucil or radiation therapy (range, 3-25 months). Further follow-up is warranted to evaluate response duration and late toxicity of this novel treatment strategy
Volume
4
Issue
2
First Page
115
Last Page
118
ISSN
1526-9655
Published In/Presented At
Ibom, V., Prosnitz, R. G., Gong, J., Moore, J., DeCastro, C., Prosnitz, L., Rizzieri, D., & Gockerman, J. (2003). Rituximab in lymphocyte predominance Hodgkin's disease: a case series.. LVHN Scholarly Works. Retrieved from https://scholarlyworks.lvhn.org/radiation-oncology/44
Disciplines
Medicine and Health Sciences | Oncology
PubMedID
14556684
Department(s)
Department of Radiation Oncology
Document Type
Article